Ultra-sensitive tests now reveal changes in biomarkers like Aβ and tau in AD, or phosphorylated alpha-synuclein in PD, long before symptoms appear, providing a precious opportunity for early intervention. This evidence concerns the gene MAPT and Alzheimer disease.